148 related articles for article (PubMed ID: 33787635)
21. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
22. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
23. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
[TBL] [Abstract][Full Text] [Related]
25. Oligodendroglioma showing pleomorphic xanthoastrocytoma-like perivascular microlesion: With IDH1, TERT promoter mutation and 1p/19q codeletion detected in both components.
Murakami C; Ikota H; Nobusawa S; Nakata S; Yamazaki T; Hashiba Y; Hirato J; Yokoo H
Pathol Int; 2020 Jan; 70(1):40-46. PubMed ID: 31855307
[TBL] [Abstract][Full Text] [Related]
26. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
27. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
29. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
31. Adult classical glioblastoma with a BRAF V600E mutation.
Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma multiforme in pregnancy.
Mackenzie AP; Levine G; Garry D; Figueroa R
J Matern Fetal Neonatal Med; 2005 Jan; 17(1):81-3. PubMed ID: 15804792
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
34. Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma.
Petrovich NM; Holodny AI; Brennan CW; Gutin PH
AJNR Am J Neuroradiol; 2004 Jan; 25(1):130-3. PubMed ID: 14729542
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis-related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation?
Coskun S; Gamsizkan M; Yilmaz I; Yalcinkaya U; Sungur MA; Buyucek S; Onal B
APMIS; 2020 Sep; 128(9):515-522. PubMed ID: 32580246
[TBL] [Abstract][Full Text] [Related]
36. Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
Yoshikawa A; Nakada M; Watanabe T; Hayashi Y; Sabit H; Kato Y; Suzuki S; Ooi A; Sato H; Hamada J
Brain Tumor Pathol; 2013 Jul; 30(3):175-9. PubMed ID: 23053494
[TBL] [Abstract][Full Text] [Related]
37. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
Funata N; Nobusawa S; Yamada R; Shinoura N
Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
[TBL] [Abstract][Full Text] [Related]
38. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
39. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
40. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
